Incyte's povorcitinib, an oral JAK1 inhibitor, demonstrates promising results in phase 3 trials for hidradenitis suppurativa, potentially offering a new alternative treatment option.
The FDA's 2025 pulse oximetry guidance introduces stricter accuracy standards, larger study cohorts, and objective skin pigmentation assessment to address measurement bias in darker-skinned patients.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
FDA approves a prefilled syringe format for Purified Cortrophin Gel, reducing administration steps for patients with inflammatory and autoimmune conditions.
2023 brought record-breaking heat waves in the United States, significantly impacting vulnerable groups. Analysis by the CDC revealed a substantial number of heat-related illness (HRI) emergency department visits, resulting in multiple public health alerts.